As a result of increasing competition, a smaller player (in the biosimilar field) is seeking to sell its nascent biosimilar business.
As a result of increasing competition, a smaller player (in the biosimilar field) is seeking to sell its nascent biosimilar business. Merck KGaA (which operates in the US as EMD Serono and is not associated with Merck & Company) has engaged the services of the investment banker JP Morgan Chase to seek potential buyers for its biosimilar unit.
Merck KGaA has decided to fortify its pipeline efforts instead on multiple sclerosis, where it has a strong marketing position with its product Rebif®, and in several cancer therapeutic approaches. The company’s only late-stage biosimilar is adalimumab (MSB11022), which is currently involved in a phase 3 trial with 400 patients that is supposed to be completed by September 2017. The primary endpoint results are slated to be available, however, in December 2016.
According to the announcement, the company’s biosimilars business could be valued at as much as $1 billion, not only based on its adalimumab agent but several undisclosed early-stage biosimilars. However, Merck may not make a big splash with its key product, as Amgen’s adalimumab has already been approved, and it may be one of several biosimilar versions to hit the market in the next few years, pending clearance of patent litigation.
In other news…Active biosimilar player Celltrion, from South Korea, has announced its submission of an application to the European Medicines Agency to license its version of Herceptin®. Interestingly, although it is approved for use in South Korea under the brand name Herzuma®, this biosimilar only commenced phase 1 trials in the US in September for eventual application to the Food and Drug Administration. No timetable has been announced for US submission.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.